BG102781A - Isolated dimer fibroblastactivation protein alpha and its application - Google Patents

Isolated dimer fibroblastactivation protein alpha and its application

Info

Publication number
BG102781A
BG102781A BG102781A BG10278198A BG102781A BG 102781 A BG102781 A BG 102781A BG 102781 A BG102781 A BG 102781A BG 10278198 A BG10278198 A BG 10278198A BG 102781 A BG102781 A BG 102781A
Authority
BG
Bulgaria
Prior art keywords
application
fibroblastactivation
protein alpha
isolated dimer
dimer
Prior art date
Application number
BG102781A
Other languages
Bulgarian (bg)
English (en)
Inventor
Rainer Zimmerman
John Park
Wolfgang Rettig
Lloyd Old
Original Assignee
Ludwig Institute For Cancer Research
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute For Cancer Research, Boehringer Ingelheim International Gmbh filed Critical Ludwig Institute For Cancer Research
Publication of BG102781A publication Critical patent/BG102781A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
BG102781A 1996-03-18 1998-09-18 Isolated dimer fibroblastactivation protein alpha and its application BG102781A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/619,280 US5767242A (en) 1994-04-20 1996-03-18 Isolated dimeric fibroblast activation protein alpha, and uses thereof
PCT/US1997/004215 WO1997034927A1 (en) 1996-03-18 1997-03-12 Isolated dimeric fibroblast activation protein alpha, and uses thereof

Publications (1)

Publication Number Publication Date
BG102781A true BG102781A (en) 1999-09-30

Family

ID=24481231

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102781A BG102781A (en) 1996-03-18 1998-09-18 Isolated dimer fibroblastactivation protein alpha and its application

Country Status (23)

Country Link
US (2) US5767242A (de)
EP (1) EP0960127B1 (de)
JP (1) JP4102441B2 (de)
KR (1) KR20000064655A (de)
CN (1) CN1214052A (de)
AT (1) ATE449106T1 (de)
AU (1) AU729369B2 (de)
BG (1) BG102781A (de)
BR (1) BR9708100A (de)
CA (1) CA2242342C (de)
CZ (1) CZ299698A3 (de)
DE (1) DE69739665D1 (de)
DK (1) DK0960127T3 (de)
EE (1) EE03693B1 (de)
ES (1) ES2334183T3 (de)
HU (1) HUP0104468A3 (de)
IL (1) IL125124A0 (de)
NO (1) NO984298L (de)
NZ (2) NZ331758A (de)
PL (1) PL328947A1 (de)
SK (1) SK126798A3 (de)
TR (1) TR199801845T2 (de)
WO (1) WO1997034927A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
HK1046846A1 (zh) * 1999-05-25 2003-01-30 Point Therapeutics, Inc. 包含boroproline的抗肿瘤复合物
EP1806138A1 (de) * 1999-05-25 2007-07-11 Point Therapeutics, Inc. Anti-tumor präparate enthaltend boroprolin verbindungen
US20030092890A1 (en) * 1999-07-28 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
JP2004536835A (ja) * 2001-07-09 2004-12-09 アフトン コーポレーション 肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止
US7691967B2 (en) 2002-04-30 2010-04-06 Trustees Of Tufts College Smart pro-drugs of serine protease inhibitors
WO2004004661A2 (en) * 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
US7309774B2 (en) 2003-02-07 2007-12-18 The Board Of Regents Of The University Of Oklahoma Antiplasmin cleaving enzyme
US20080057491A1 (en) * 2003-02-07 2008-03-06 Mckee Patrick A Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use
US7235376B2 (en) * 2003-03-28 2007-06-26 Receptor Biologix, Inc. Gastrin hormone immunoassays
US20060020119A1 (en) * 2004-03-29 2006-01-26 Stephen Grimes Monoclonal antibodies to gastrin hormone
WO2005071073A1 (en) * 2004-01-09 2005-08-04 Point Therapeutics, Inc. Fap compositions and the use thereof for immunomodulation
US20090010919A1 (en) * 2004-07-29 2009-01-08 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated With Fibroblast Activation Protein (Fap)
EP2567974A3 (de) 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoklonale Antikörper gegen Progastrin
US20090238862A1 (en) * 2004-10-27 2009-09-24 Wen-Tien Chen Methods and Compositions for Seprase Inactivation
PL1824991T3 (pl) 2004-11-24 2016-08-31 Techlab Inc Urządzenie oraz sposób do wykrywania analitów
US8067248B2 (en) 2005-12-14 2011-11-29 Luwig Institute for Cancer Research Method for diagnosing rheumatoid arthritis via assaying myofibroblast-like synoviocytes for fibroblast activation protein
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
PT2035581E (pt) * 2006-06-21 2012-12-06 Scripps Research Inst Composição de adn contra o antigénio do estroma tumoral fap e métodos de utilização desta
CA2753884A1 (en) 2009-02-27 2010-09-02 Trustees Of Tufts College Soft protease inhibitors, and pro-soft forms thereof
CN104884091B (zh) 2012-12-28 2021-07-20 科比欧尔斯公司 最低毒性的药物前体
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
IL325256A (en) 2014-06-13 2026-02-01 Bach Biosciences Llc FAP-activated medical materials and related uses
CN105859866B (zh) * 2016-05-27 2019-08-13 郑州大学 Fap来源的抗肿瘤ctl表位肽p265及其应用
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質(fap)標的イメージングおよび治療
IL271427B2 (en) 2017-06-15 2025-08-01 Cancer Advances Inc Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
AU2021405744A1 (en) 2020-12-22 2023-08-03 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1320734C (en) * 1986-02-04 1993-07-27 Suntory Limited Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same
US5587299A (en) * 1994-04-20 1996-12-24 Memorial Sloan-Kettering Cancer Center Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof

Also Published As

Publication number Publication date
NZ335543A (en) 2001-03-30
HUP0104468A3 (en) 2004-10-28
IL125124A0 (en) 1999-01-26
EE03693B1 (et) 2002-04-15
CA2242342C (en) 2013-05-14
EP0960127A4 (de) 2004-09-08
BR9708100A (pt) 2000-01-04
JP4102441B2 (ja) 2008-06-18
DK0960127T3 (da) 2010-03-29
PL328947A1 (en) 1999-03-01
US5767242A (en) 1998-06-16
NO984298D0 (no) 1998-09-17
EP0960127A1 (de) 1999-12-01
HUP0104468A2 (hu) 2002-04-29
AU729369B2 (en) 2001-02-01
CA2242342A1 (en) 1997-09-25
CZ299698A3 (cs) 1999-01-13
AU2330297A (en) 1997-10-10
ATE449106T1 (de) 2009-12-15
EP0960127B1 (de) 2009-11-18
EE9800306A (et) 1999-02-15
WO1997034927A1 (en) 1997-09-25
US5965373A (en) 1999-10-12
NZ331758A (en) 2000-01-28
KR20000064655A (ko) 2000-11-06
TR199801845T2 (xx) 1998-12-21
NO984298L (no) 1998-09-17
DE69739665D1 (de) 2009-12-31
ES2334183T3 (es) 2010-03-05
JP2000507100A (ja) 2000-06-13
CN1214052A (zh) 1999-04-14
SK126798A3 (en) 1999-05-07

Similar Documents

Publication Publication Date Title
IL125124A0 (en) Dimeric forms of the protein fapalpha and uses thereof
NO964966D0 (no) Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav
ES2195970T3 (es) L-ribavirina y usos de la misma.
YU15299A (sh) Farmaceutski sastavi
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
IL127918A0 (en) Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
AR016981A2 (es) Polipeptidos sinteticos
MX9204623A (es) Compuesto de bis-4-piperidil-fosfita n-metilada.
BG101787A (en) Aprotinine options having improved properties
TR199900430T2 (xx) �kameli 1,2,3,4-tetrahidro-2-dibenzofuranaminler ve 2-aminosiklohepta$b] benzofuranlar.
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
BG104373A (en) Polymorphous forms of dofetilide
HUT73328A (en) Rye-flour
PE20399A1 (es) Muteina ob
BG102937A (en) Zona pelucida proteins as contraceptives
AU7233296A (en) Streptoccal inhibitor of complement-mediated lysis, protein sic
ZA978233B (en) The use of protein as anti-retroviral agents.
MX9602767A (es) Dimaleato de n,n-dietil-8,8-dipropil-2-azaspiro[4,5]decano-2-propanamina.
FR2717391B1 (fr) Peptides pour inhiber la libération de pepsine.
IT1289633B1 (it) Composizione e procedimento per la fabbricazione di manufatti cementizi.
MX9800981A (es) Promotor del gen de endoglina humana y su uso.
MX9702231A (es) Nuevos trimeros de isocianato y mezclas de trimeros de isocianato, su obtencion y empleo.
ES1032970Y (es) Cuerpo recreativo de poliedros.
ITFE930013U1 (it) Bacchette orientali meccanizzate.